All In Biotech

NDA 204326 · Neos Theraps

Adzenys Xr-Odt

Amphetamine · Oral · Central Nervous System Stimulant

Last checked: Nov 20, 2026Latest source record: Sep 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Jan 27, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

392

60 Phase 3, 36 recruiting

FAERS reports

6,299

5,284 serious, 3,007 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ABUSE, MISUSE AND ADDICTION Amphetamine extended-release orally disintegrating tablets has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including amphetamine extended-release orally disintegrating tablets, can result in overdose and death [ see Overdosage ( 10 )], and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing amphetamine extended-release orally disintegrating tablets, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout amphetamine extended-release orally disintegrating tablets treatment, reassess each patient’s risk of abuse, misuse, and...

What it is approved for

From the label in effect Oct 1, 2026.

Amphetamine extended-release orally disintegrating tablets is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older [see Clinical Studies ( 14 )]. Limitations of Use The use of amphetamine extended-release orally disintegrating tablets is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g. weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions (5.5). Use in Specific Populations (8.4) ]. Amphetamine extended-release orally disintegrating tablets is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older. ( 1 ) Limitations of Use The use of amphetamine extended-release orally disintegrating tablets is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage. (5.5, 8.4)

Mechanism: Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in ADHD is not known. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 27, 2016 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
6 products under this application
  • ADZENYS XR-ODT · AMPHETAMINE EQ 18.8MG BASE · TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • ADZENYS XR-ODT · AMPHETAMINE EQ 12.5MG BASE · TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • ADZENYS XR-ODT · AMPHETAMINE EQ 6.3MG BASE · TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • ADZENYS XR-ODT · AMPHETAMINE EQ 15.7MG BASE · TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • ADZENYS XR-ODT · AMPHETAMINE EQ 9.4MG BASE · TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • ADZENYS XR-ODT · AMPHETAMINE EQ 3.1MG BASE · TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Amphetamine" as an intervention, any sponsor and status, largest first.

All 392 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • toxicity to various agents1,620
  • drug abuse1,301
  • completed suicide666
  • overdose409
  • death354
  • cardiac arrest280
  • cardio-respiratory arrest266
  • drug ineffective237
  • respiratory arrest216
  • fatigue203
  • drug dependence188
  • drug interaction185

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200417
200512
200613
200715
200816
20091
20107
201142
201236
2013227
2014264
2015393
2016258
2017327
2018439
2019498
2020507
2021417
2022463
2023512
2024673
2025751
2026411

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Adzenys XR-ODT (Amphetamine)

2024 spending

$1.1M

Beneficiaries

367

2,030 claims

Per beneficiary

$3,082

$16.15 per unit

View as table
YearSpending
2020$490,523
2021$545,688
2022$576,313
2023$1,168,346
2024$1,131,274

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,104 on PubMed

Sponsor: Neos Theraps

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.